Pioglitazone [20], semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA) [21], tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist (GIP/GLP-1RA) [22], and tofogliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i) [23], have all been shown to improve liver function in participants with liver dysfunctions, including NAFLD, NASH (MASH), and hepatic fibrosis, as demonstrated in randomized controlled trials (RCTs). This evidence concerns the gene SLC5A2 and Hepatic fibrosis.